Crossmark

Combined Impact of Neoadjuvant Therapy and Preoperative Cachexia in Patients Undergoing Pancreatoduodenectomy: Is There a “Double Jeopardy”? A National Cohort Study Investigating the Association with Short- and Long-Term Outcomes

Crossref DOI link: https://doi.org/10.1245/s10434-025-18941-y

Published Online: 2026-01-05

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Roalsø, Marcus Thomas Thor https://orcid.org/0000-0002-4689-4412
Oanaes, Celine

Garresori, Herish

Edland, Karin Hestnes

Dalen, Ingvild

Hagland, Hanne Røland

Søreide, Kjetil
Funding

Funding for this research was provided by:

Helse Vest (#F-12625)

Folke Hermansen Fund for Cancer Research

University of Stavanger & Stavanger University Hospital
License Information

Text and Data Mining valid from 2026-01-05

Version of Record valid from 2026-01-05
More Information

Article History

Received: 23 September 2025

Accepted: 9 December 2025

First Online: 5 January 2026

Disclosure

: Dr. Garresori has received honoraria from Ipsen, Amgen, Pfizer, Bristol Myers Squibb, AstraZeneca, Pierre Fabre, and Daiichi Sankyo for educational presentations or organizing multidisciplinary team meetings. The other authors have no conflicts of interest to declare.

: Data from the Norwegian Registry of Gastrointestinal Surgery (NORGAST) has been used in this publication. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by NORGAST is intended nor should it be inferred.

Document is current

Any future updates will be listed below